Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

ClinicalTrials.gov ID: NCT01479465

Public ClinicalTrials.gov record NCT01479465. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 8:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma That Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen

Study identification

NCT ID
NCT01479465
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Gilead Sciences
Industry
Enrollment
266 participants

Conditions and interventions

Interventions

  • Simtuzumab Biological
  • Placebo to match SIM Drug
  • Leucovorin Drug
  • Irinotecan Drug
  • Fluorouracil Drug

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2011
Primary completion
Sep 30, 2014
Completion
Jan 31, 2015
Last update posted
Apr 16, 2019

2011 – 2015

United States locations

U.S. sites
56
U.S. states
26
U.S. cities
52
Facility City State ZIP Site status
Clearview Cancer Institute Huntsville Alabama 35801
Banner MD Anderson Cancer Center Gilbert Arizona
Central Hematology Oncology Medical Group, Inc. Alhambra California
Comprehensive Blood and Cancer Center Bakersfield California
Providence Saint Joseph Medical Center-Disney Family Cancer Center Burbank California
Wilshire Oncology Medical Group, Inc. Corona California
Saint Jude Heritage Healthcare Fullerton California
University of California San Diego Medical Center La Jolla California
Pacific Shores Medical Group Long Beach California
Comprehensive Hematology Oncology Centers, Inc. Los Angeles California
TORI Network (Translational Oncology Research Intl) Los Angeles California
UCLA Community Oncology Practice Los Angeles California
Stanford University Medical Center Palo Alto California
Wilshire Oncology Medical Group, Inc. Pomona California
Cancer Care Associates Medical Group Redondo Beach California
Pacific Shores Medical Group Redondo Beach California
Sharp Health Care San Diego California
San Jose Medical Group San Jose California
Central Coast Medical Oncology Corp Santa Maria California
Yale University Smilow Cancer Hospital New Haven Connecticut 06520
Georgetown University Washington D.C. District of Columbia
Florida Cancer Specialists Gainesville Florida
MD Anderson Cancer Center Orlando Florida
Florida Cancer Specialists St. Petersburg Florida
Peachtree Hematology Oncology Consultants, PC Atlanta Georgia
Suburban Hematology Oncology Associates, PC Lawrenceville Georgia
Northwestern University Chicago Illinois
Indiana University Simon Cancer Center Indianapolis Indiana
Tufts Medical Center Boston Massachusetts 02111
Dana Farber Cancer Institute Boston Massachusetts
West Michigan Cancer Center Kalamazoo Michigan
Hematology and Oncology Associates at BridgePoint Tupelo Mississippi
Saint Joseph Oncology, Inc. Saint Joseph Missouri
Montana Cancer Institute Missoula Montana 59802
Southeast Nebraska Cancer Center Lincoln Nebraska
Comprehensive Cancer Centers of Nevada Henderson Nevada
Comprehensive Cancer Centers of Nevada Las Vegas Nevada
New York University Clinical Cancer Center New York New York 10016
Oncology Hematology Care, Inc. Cincinnati Ohio
Signal Point Clinical Research Center, LLC Middletown Ohio
Oncology Hematology Care, Inc. Wilmington Ohio
Kaiser Permanente Northwest Region Oncology Hematology Portland Oregon
South Carolina Oncology Associates Columbia South Carolina
Tennessee Oncology, PLLC Nashville Tennessee
University of Texas Southwestern Medical Center at Dallas Dallas Texas
Center for Cancer and Blood Disorders, PC Fort Worth Texas
Joe Arrington Cancer Research and Treatment Center Lubbock Texas
Scott & White Memorial Temple Texas 76508
The Center for Cancer and Blood Disorders Weatherford Texas
Utah Cancer Specialists Salt Lake City Utah
Intermountain Healthcare St. George Utah
Virginal Cancer Specialists, PC Fairfax Virginia 22033
Virginia Cancer Institute Midlothian Virginia
Virginia Cancer Institute Richmond Virginia
Seattle Cancer Care Alliance Seattle Washington
University of Wisconsin Madison Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01479465, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 16, 2019 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01479465 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →